ALS (ASX:ALQ) acquires stake in Euro pharmaceutical firm

Company News

by Lauren Evans

Testing services provider ALS (ASX:ALQ) has acquired a 49 per cent interest in NUVISAN, a Germany-based pharmaceutical testing firm.

The acquisition aims to expand ALS's life sciences service offering and footprint in Europe. 

NUVISAN generated revenue of EUR 185 million in FY21 and has over 1,000 employes. The company operates in research, development and manufacturing markets, providing drug testing services throughout the pharmaceutical development cycle.

The acquisition also aims to expand ALS's testing into up stream research and development, which constitutes the majority of client spend. 

Shares in ALS (ASX:ALQ) are trading 0.2 per cent higher at $12.57.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.